Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Total Debt (2024 - 2025)

Historic Total Debt for Apellis Pharmaceuticals (APLS) over the last 2 years, with Q3 2025 value amounting to $454.7 million.

  • Apellis Pharmaceuticals' Total Debt rose 2665.59% to $454.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $454.7 million, marking a year-over-year increase of 2665.59%. This contributed to the annual value of $359.5 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Apellis Pharmaceuticals' Total Debt is $454.7 million, which was up 2665.59% from $360.5 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Total Debt ranged from a high of $454.7 million in Q3 2025 and a low of $359.0 million during Q3 2024